A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology. (31st December 2022)

• Record Type: Journal Article
• Authors: Sprooten, Jenny; Coosemans, An; Garg, Abhishek D.
• Is Part Of: Oncoimmunology. Volume 11:Number 1(2022)
• Publication Date: 2022-12-31
• Subjects: Immunosurveillance -- anticancer immunity -- inhibitory receptors -- lymphocytes -- benign or borderline lesions -- immunology -- neutrophils -- wound healing -- TGFB1 -- pattern-recognition receptors (PRRS) -- ovarian canc er; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2021.2024692
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient's blood milieu with immuno-oncological applications are rare. We recently established a "first-in-class" serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to "mimic" in situ patient's serum immune-biology. This modality has clear implications for anticipating patient prognosis and immunotherapy-relevant stratification.